CellSeed

CellSeed Rule of 40

The Rule of 40 of CellSeed (7776.T) as of Oct 27, 2026 is -1,306.89 %. In the previous year, Rule of 40 was -436.26 % — a change of 199.57% (lower).

Rule of 40

-1,306.89 %

YoY

199.57%

Last updated:

Rule of 40 of CellSeed is 2025 -1,306.89 % . Rule of 40 of CellSeed was 2024 -436.26 % . It decreases by 199.57% lower compared to the previous year.

The CellSeed Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
1,119.95 JPY
Jan 1, 2019
-372.58 JPY
Jan 1, 2020
-413.46 JPY
Jan 1, 2021
-579.43 JPY
Jan 1, 2022
-611.76 JPY
Jan 1, 2023
-316.60 JPY
Jan 1, 2024
-436.26 JPY
Jan 1, 2025
-1,306.89 JPY
The CellSeed Rule of 40 history
YEARRule of 40YoY
-1,306.89 %+199.57%
-436.26 %+37.79%
-316.60 %-48.25%
-611.76 %+5.58%
-579.43 %+40.14%
-413.46 %+10.97%
-372.58 %-133.27%
1,119.95 %-197.93%
-1,143.58 %+11.49%
-1,025.77 %+503.81%
-169.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

Rule of 40 of CellSeed is -1,306.89 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 CellSeed since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — CellSeed

All Key Metrics — CellSeed